Further, on January 25, 2016, SIRF published an article alleging that Insys's executives have continued to pressure Company employees to develop new schemes to promote the illegal and improper off-label marketing and sale of Subsys. On this news, the price of the Company's shares declined an additional $1.07 per share, or nearly 5%, to close at $21.58 per share on January 25, 2016.
If you are a shareholder of Insys Therapeutics and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at:
You may also contact Robert H. Lefkowitz, Esq. either via email at email@example.com or by telephone at 212-725-1000. One of our attorneys will personally speak with you about the case at no cost or obligation.
Purcell Julie & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct. For more information about the firm and its attorneys, please visit http://pjlfirm.com. Attorney advertising. Prior results do not guarantee a similar outcome.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/purcell-julie--lefkowitz-llp-is-investigating-insys-therapeutics-inc-for-potential-breaches-of-fiduciary-duty-by-its-board-of-directors-300319892.html
SOURCE Purcell Julie & Lefkowitz LLP